Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NETSPOT vs FDG-PET in head and neck cancer
NCT03602911Phase 2Completed
- Sponsor
- West Virginia University
- Start
- Feb 2019
- Primary completion
- Apr 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gallium ga 68 dotatate in head and neck squamous cell carcinoma (HNSCC), sponsored by West Virginia University. Primary endpoint: Standard Uptake Value at 7 days. Started Feb 2019; status: completed.
02
Drugs
gallium ga 68 dotatate
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03602911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03602911.